BioSpace News Archive

The notification states that the US patent 9,895,234 will be granted and enters into force on February 20, 2018.

Dr. Reddy’s Laboratories announced today that it has launched Tetrabenazine Tablets, a therapeutic equivalent generic version of Xenazine® (tetrabenazine) in the United States market approved by the U.S. Food and Drug Administration (USFDA).

Under the agreement signed, Innovus Pharma will be selling certain of its products directly to Wellmed’s current 500,000 customers and utilizing Wellmed’s access to a database of over 5 million additional potential consumers for a fixed cash fee if certain net revenue targets are met as a result of the direct mailing campaigns.

Sosei today announced that it will be restating selected financial statements previously issued by the Company.

He will replace Giorgio Negri, Interim CFO, previously announced in 2017.

Worldwide sales were $10.4 billion for the fourth quarter of 2017, an increase of 3 percent compared with the fourth quarter of 2016, including a 1 percent positive impact from foreign exchange.

The first case coincides with the naming of seasoned medical device executive, Peter Sommerness, as CEO of Respicardia and leader of the remede System U.S. launch.

Portage Pharmaceuticals is providing an undisclosed funding to the new business along with a limited license to its CellPorter peptide delivery technology.

Acorda will host a conference call and webcast to report its fourth quarter 2017 financial results and pipeline updates on Thursday, February 15 at 8:30 a.m. ET.

Fremanezumab is a quarterly or monthly injection that may be administered by a healthcare professional, or self-administered by the patient.